Leading Sanofi Pasteur pediatric combo vaccine is to be produced in Russia first

- Nanolek and Sanofi Pasteur localize vaccines’ production in Russia -

June 19, 2015, Saint Petersburg - Sanofi Pasteur, the vaccines division of Sanofi, and NANOLEK (ROSNANO project company) have signed a Memorandum of Understanding to produce vaccines in Russia during the International Economic Forum in Saint Petersburg.

Sanofi Pasteur, one of the world leader in the development and production of vaccines and prevention of infectious diseases, plans to produce the 5-in-1 combo vaccine Pentaxim® in Russia jointly with Nanolek. Pentaxim® is a combined vaccine which is administrated in pediatric use to infants in order to enable protection against 5 serious infectious diseases in one injection (diphtheria, tetanus, pertussis, poliomyelitis, infection caused by Haemophilus influenza type b).

Pentaxim® is #1 modern pediatric vaccine in commercial segment of Russian market. Pentaxim® is registered and used by pediatricians in more than 100 countries in the world. Pentaxim® is included in immunization programs of leading developed countries all over the world. In Russia, the vaccine has been registered and widely used in pediatric practice since 2008.

“Sanofi Pasteur, the world market leader in vaccines, has demonstrated to be a serious partner and investor in healthcare system in Russia. Today Sanofi Pasteur and Nanolek are happy to announce the signature of a Memorandum of Understanding to transfer the technology to produce Pentaxim® in Russia. Sanofi Pasteur and Nanolek are investing in the production of Pentaxim® in Russia in order to enable access to a free, safe and efficacious vaccine to all Russian children”, - said Olivier Charmeil, CEO Sanofi Pasteur.

Pentaxim® production is planned at the plant of Nanolek in the Kirov’s region.

“The opening of the production on such a high level and NANOLEK activity in general are of great importance for our region, - said Nikita Belikh. - Because it is well-equipped production facilities, working steadily; more jobs, ensuring decent wages; this is the production of essential drugs in an industrial volume. The regional government highly appreciates the activity of the company and is ready to continue supporting its development in the future.”
“Our partnership with one of the world largest manufacturers of vaccines, Sanofi Pasteur, is a very important step of NANOLEK development, which we're very proud of, - said Vladimir Khristenko, President NANOLEK - Our biopharmaceutical production facility in Kirov is an ideal platform for such a complicated process as a localization of a combined vaccine manufacturing. NANOLEK plant was built from the scratch, according to the international standards of quality (GMP) and its capacity for sterile products is among the largest in Russia. Pentaxim® vaccine produced by NANOLEK is aimed to reach the volume of 10 mln doses per year in a near future”.

Inclusion of Pentaxim® in the National Vaccination Schedule could bring significant economic and healthcare benefits such as reduced direct and indirect economic losses caused by the burden of diseases, lower cost of vaccine storage and transportation, reduced workload for doctors and hospitals, fewer hospital admissions and visits to the doctors. Pentaxim®’s administration allows to reduce number of injections for infants by one third.

“At the moment, almost one infant out of five in Russia is already vaccinated with Pentaxim® in the commercial segment via private and state clinics. Sanofi Pasteur’s ambition is to make Pentaxim® accessible for free for all kids in Russia, – said Thibault Crosnier-Leconte, General Manager of Sanofi Pasteur in Russia. –Through this technology transfer investment, Sanofi Pasteur reinforce its commitment of being a key partner for public health”.

All diseases covered by Pentaxim® are already included in the Russian National Vaccination Schedule. Pentaxim® is administrated in all Russian regions.

About Sanofi

Sanofi, a global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients’ needs. Sanofi has core strengths in diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and Genzyme. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

About Sanofi Pasteur

Sanofi Pasteur, the vaccines division of Sanofi, provides more than 1 billion doses of vaccine each year, making it possible to immunize more than 500 million people across the globe. A world leader in the vaccine industry, Sanofi Pasteur offers a broad range of vaccines protecting against 20 infectious diseases. The company's heritage, to create vaccines that protect life, dates back more than a century. Sanofi Pasteur is the largest company entirely dedicated to vaccines. Every day, the company invests more than EUR 1 million in research and development. For more information, please visit: www.sanofipasteur.com or www.sanofipasteur.us.

About NANOLEK

NANOLEK is a fast-growing Russian pharmaceutical company that aims to take a leading position for the production of innovative biotech drugs and vaccines today, helping to create a national bioeconomy.
The production site BMK “Nanolek”:
Levinta village, Orichevsky district, Kirov region

Start of production: December 2014
The volume of investments: 6 billion. RUR
The area of 14 hectares
The total area of the enterprise: 28 000 square meters
Compliance EU GMP, ISO
Staff in 2015: 250 employees

Full-cycle production:
STA (capsules and tablets), inactivated and recombinant vaccines, biotechnological PL

Production in the year:
• 1 billion pills / capsules
• 42 million prefilled syringes
• 35 million vials

Media contacts

Sanofi Russia
Communications department
+7 (495) 721-14-00
Sanofi.Russia@sanofi.com
www.sanofi.ru

Nanolek
Elena Koltsova, Head of corporate communications
+7 (963) 605-50-34
e.koltsova@nanolek.ru
www.nanolek.ru

www.privivka.ru